Premium
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
Author(s) -
Dickinson Michael,
Ritchie David,
DeAngelo Daniel J.,
Spencer Andrew,
Ottmann Oliver G.,
Fischer Thomas,
Bhalla Kapil N.,
Liu Angela,
Parker Katie,
Scott Jeffrey W.,
Bishton Mark,
Miles Prince H.
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07837.x
Subject(s) - panobinostat , medicine , lymphoma , refractory (planetary science) , positron emission tomography , oncology , aggressive lymphoma , nuclear medicine , rituximab , histone deacetylase , biochemistry , astrobiology , gene , histone , chemistry , physics
Summary There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by 18 F‐fluoro‐2‐deoxy‐ d ‐ glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti‐tumour activity seen in the early phase of this study, which recently closed to accrual.